Epidemiological trends in invasive aspergillosis in France: The SAIF network (2005-2007)

Clinical Microbiology and Infection

Volumn 17, Issue 12, 2011, Pages 1882-1889

  Lortholary, O ^a,b,c   Gangneux, J P ^d,e   Sitbon, K ^a,b   Lebeau, B ^f   de Monbrison, F ^g   Le Strat, Y ^h   Coignard, B ^h   Dromer, F ^a,b   Bretagne, S ^a,i,j  

^a INSTITUT PASTEUR   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d CENTRE HOSPITALIER   (France)

^e UNIVERSITÉ DE RENNES 1   (France)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

^g UNIVERSITÉ DE LYON   (France)

^h INSTITUT DE VEILLE SANITAIRE   (France)

ⁱ HENRI MONDOR HOSPITAL   (France)

^j UNIVERSITÉ PARIS EST CRÉTEIL   (France)

more..

Author keywords

Epidemiology; Galactomannan; Invasive aspergillosis; Outcome; Voriconazole

Indexed keywords

AMPHOTERICIN; CASPOFUNGIN; GALACTOMANNAN; VORICONAZOLE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLUS FUMIGATUS; BLOOD LEVEL; CHRONIC RESPIRATORY TRACT DISEASE; DRUG FORMULATION; FEMALE; FRANCE; HEMATOLOGICAL PARAMETERS; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INFLAMMATORY DISEASE; INVASIVE ASPERGILLOSIS; LUNG DISEASE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SEASONAL VARIATION; SOLID TUMOR;

ASPERGILLUS FUMIGATUS;

EID: 81255171499     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03548.x     Document Type: Article

References (29)

1. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009; 49: 1211-1225.
2. Nivoix Y, Velten M, Letscher-Bru V et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47: 1176-1184.
3. Pappas PG, Alexander BD, Andes DR et al. Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (transnet). Clin Infect Dis 2010; 50: 1101-1111.
4. Silveira FP, Husain S. Fungal infections in solid organ transplantation. Med Mycol 2007; 45: 305-320.
5. Segal BH. Aspergillosis. N Engl J Med 2009; 360: 1870-1884.
6. Guinea J, Torres-Narbona M, Gijon P et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect 2010; 16: 870-877.
7. Cornillet A, Camus C, Nimubona S et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006; 43: 577-584.
8. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007; 45: 205-216.
9. Lortholary O, Meyohas MC, Dupont B et al. Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases. French cooperative study group on aspergillosis in aids. Am J Med 1993; 95: 177-187.
10. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
11. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis 2008; 46: 1813-1821.
12. Neofytos D, Horn D, Anaissie E et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter prospective antifungal therapy (path) alliance registry. Clin Infect Dis 2009; 48: 265-273.
13. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47: 1041-1050.
14. Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the seifem B-2004 study--sorveglianza epidemiologica infezioni fungine nelle emopatie maligne. Clin Infect Dis 2007; 45: 1161-1170.
15. Panackal AA, Li H, Kontoyiannis DP et al. Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis 2010; 50: 1588-1597.
16. Cornet M, Fleury L, Maslo C, Bernard JF, Brucker G. Epidemiology of invasive aspergillosis in france: a six-year multicentric survey in the greater paris area. J Hosp Infect 2002; 51: 288-296.
17. Patterson TF, Kirkpatrick WR, White M et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Aspergillus study group. Medicine (Baltimore) 2000; 79: 250-260.
18. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42: 1417-1427.
19. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40: 1762-1769.
20. Stergiopoulou T, Meletiadis J, Roilides E et al. Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol 2007; 127: 349-355.
21. Cordonnier C, Botterel F, Ben Amor R et al. Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis. Clin Microbiol Infect 2009; 15: 81-86.
22. Perfect JR, Cox GM, Lee JY et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001; 33: 1824-1833.
23. Pagano L, Caira M, Candoni A et al. Invasive aspergillosis in patients with acute myeloid leukemia: a seifem-2008 registry study. Haematologica 2010; 95: 644-650.
24. Baddley JW, Andes DR, Marr KA et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 2010; 50: 1559-1567.
25. Cordonnier C, Ribaud P, Herbrecht R et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at french transplantation centers. Clin Infect Dis 2006; 42: 955-963.
26. Parody R, Martino R, Sanchez F, Subira M, Hidalgo A, Sierra J. Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: single-center analysis and validation of the seattle, french, and strasbourg prognostic indexes. Am J Hematol 2009; 84: 571-578.
27. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373-379.
28. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of america. Clin Infect Dis 2008; 46: 327-360.
29. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.